Condition: Chronic Rhinosinusitis With Nasal Polyps · Sponsor: Upstream Bio Inc.
The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Sensa Health LA (Sensa Health Clinical Research) | Los Angeles, California, United States | — |
| NewportNativeMD, Inc. | Newport Beach, California, United States | — |
| DaVinci, Research LLC | Roseville, California, United States | — |
| Senta Clinic | San Diego, California, United States | — |
| University of Missouri | Columbus, Colorado, United States | — |
| Western States Clinical Research, Inc. | Wheat Ridge, Colorado, United States | — |
| Alfa Medical Research | Hollywood, Florida, United States | — |
| Novaceut Clinical Research | Miami, Florida, United States | — |
| Well Pharma Medical Research Corp. | Miami, Florida, United States | — |
| IMIC Inc. | Miami, Florida, United States | — |
| University of South Florida | Tampa, Florida, United States | — |
| Treasure Valley Medical Research | Boise, Idaho, United States | — |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06164704